Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level

References

• Nishihimoto N, Hashimoto J, Miyasaka N, Yamamotro K, Kawai S, Kishimoto T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   Google Scholar
• Nishimoto N, Terao K, Nakahara H, Takagi N, Kakehi T. Mechanism and pathologic significances in increase in serum interleukin-6(IL-6) and soluble 11–6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112: 3959–64.
   Google Scholar
• Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Smolen JS, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:796–806.
   PubMed Web of Science ®Google Scholar
• Alethaha D, Smolen JS. The simple disease activity index (SDAI) and the clinical disease activity index (CDAI). A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheu-matol. 2005;23(Suppl 39):S100–8.
   Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2004;50: 1761–9.
   PubMed Web of Science ®Google Scholar
• Smolen SJ, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Ro-vensky J, Alecock E. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Yamanaka H, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheuma-toid arthritis patients in a prospective observational cohort IOR-RA. Mod Rheumatol. 2007;17:403–8.
   PubMedGoogle Scholar
• Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 levels in com-parison to C-reactive protein in periods with and without pro-gression of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21: 465–72.
   Google Scholar
• Posthumus MD, Limburg PC, Westra J, Leeuwen MA, Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological pro-gression. J Rheumatol. 2000;27: 2761–8.
   Google Scholar
• Ribbens C, Andre B, Jaspar JM, Kaya 0, Kaiser MJ, Malaise MG, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol. 2000;27: 888–93.
   Google Scholar
• Sugiyama E. Clinical usefulness of serum levels of MMP-3 and IL-6 in rheumatoid arthritis. Ryumachiika. 1998;20:575–80.
   Google Scholar
• Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Wolfe E, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35:1015–22.
   PubMed Web of Science ®Google Scholar
• Sokka T, Hetland ML, Makinen H, Kautiainen H, Horslev-Pet-ersen K, Pincus T, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008;58:2642–51.
   Google Scholar
• Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of RADAI, a self-administered rheumatoid arthritis dis-ease activity index. Rheumatology. 2000;39:321–7.
   PubMed Web of Science ®Google Scholar
• Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rinthelen B. Patients-centered rheumatoid arthritis disease activity assessment by modified RADAI. J Rheumatol. 2008;35:1294–9.
   Google Scholar
• Stucki G, Liang MH, Stucki S, Bruhlmann P, Michl B. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum. 1995;38:795–8.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observation studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 2005;32:2410–5.
   Google Scholar
• Pincus T, Swearingen C, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patients Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Pro-posed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35: 2136–47.
   PubMed Web of Science ®Google Scholar
• Hussiau FK, Devogelaer JP, Van Damme J, de Dexchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784–8.
   Google Scholar
• Madhok R, Crilly A, Watoson J, Cape11 HA. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and labo-ratory indices of disease activity. Ann Rheum Dis. 1993;52: 232–4.
   Google Scholar
• Ribbens C, Andre B, Kaya 0, Kaiser MJ, Bonnet V, Malaise MG. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology. 2000;39: 1357–65.
   Google Scholar
• Klimiuk PA, Sierakowski S, Chwie KJ. Serum interleukin 6 concentration correlates with matrix metalloproteinase and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn. 2003;109: 119–23.
   Google Scholar